EXAS – Exact Sciences Corporation
Float Short %
4.56
Margin Of Safety %
-30
Put/Call OI Ratio
0.41
EPS Next Q Diff
-0.14
EPS Last/This Y
5.93
EPS This/Next Y
0.78
Price
102.37
Target Price
104
Analyst Recom
2.81
Performance Q
62.55
Relative Volume
0.34
Beta
1.42
Ticker: EXAS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | EXAS | 101.57 | 0.54 | 0.06 | 61081 |
| 2025-12-29 | EXAS | 101.92 | 0.53 | 0.25 | 61428 |
| 2025-12-30 | EXAS | 101.91 | 0.53 | 0.09 | 61564 |
| 2025-12-31 | EXAS | 101.57 | 0.53 | 0.10 | 61719 |
| 2026-01-02 | EXAS | 101.72 | 0.53 | 0.01 | 62092 |
| 2026-01-05 | EXAS | 101.61 | 0.53 | 0.75 | 62143 |
| 2026-01-06 | EXAS | 101.64 | 0.53 | 0.80 | 62779 |
| 2026-01-07 | EXAS | 101.6 | 0.53 | 0.24 | 62825 |
| 2026-01-08 | EXAS | 101.78 | 0.53 | 0.05 | 62977 |
| 2026-01-09 | EXAS | 102.13 | 0.53 | 0.01 | 62977 |
| 2026-01-12 | EXAS | 102.25 | 0.53 | 0.18 | 63106 |
| 2026-01-13 | EXAS | 102.26 | 0.52 | 0.09 | 63667 |
| 2026-01-14 | EXAS | 102.27 | 0.52 | 0.83 | 63799 |
| 2026-01-15 | EXAS | 102.35 | 0.53 | 1.69 | 63868 |
| 2026-01-16 | EXAS | 102.43 | 0.53 | 0.59 | 63905 |
| 2026-01-20 | EXAS | 102.16 | 0.39 | 1.13 | 38623 |
| 2026-01-21 | EXAS | 102.49 | 0.39 | 0.84 | 38646 |
| 2026-01-22 | EXAS | 102.37 | 0.40 | 6.99 | 39367 |
| 2026-01-23 | EXAS | 102.37 | 0.41 | 0.67 | 39786 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | EXAS | 101.58 | 225.8 | 1179.9 | 0.34 |
| 2025-12-29 | EXAS | 101.90 | 225.8 | 1180.5 | 0.34 |
| 2025-12-30 | EXAS | 101.92 | 225.8 | 1179.7 | 0.34 |
| 2025-12-31 | EXAS | 101.57 | 225.8 | 1179.1 | 0.34 |
| 2026-01-02 | EXAS | 101.72 | 225.8 | 1180.1 | 0.34 |
| 2026-01-05 | EXAS | 101.60 | 225.8 | 1179.5 | 0.34 |
| 2026-01-06 | EXAS | 101.65 | 225.8 | 1179.9 | 0.34 |
| 2026-01-07 | EXAS | 101.60 | 225.8 | 1179.7 | 0.34 |
| 2026-01-08 | EXAS | 101.78 | 225.8 | 1180.1 | 0.34 |
| 2026-01-09 | EXAS | 102.11 | 225.8 | 1180.5 | 0.34 |
| 2026-01-12 | EXAS | 102.23 | 225.8 | 1180.0 | 0.34 |
| 2026-01-13 | EXAS | 102.26 | 225.8 | 1179.8 | 0.34 |
| 2026-01-14 | EXAS | 102.26 | 225.8 | 1179.9 | 0.34 |
| 2026-01-15 | EXAS | 102.37 | 225.8 | 1180.0 | 0.34 |
| 2026-01-16 | EXAS | 102.46 | 225.8 | 1180.0 | 0.34 |
| 2026-01-20 | EXAS | 102.37 | 225.8 | 1179.7 | 0.34 |
| 2026-01-21 | EXAS | 102.50 | 225.8 | 1180.1 | 0.34 |
| 2026-01-22 | EXAS | 102.38 | 225.8 | 1179.5 | 0.34 |
| 2026-01-23 | EXAS | 102.37 | 225.8 | 1179.4 | 0.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | EXAS | -0.89 | -4.19 | 2.76 |
| 2025-12-29 | EXAS | -0.89 | -4.15 | 2.76 |
| 2025-12-30 | EXAS | -0.89 | -4.15 | 2.76 |
| 2025-12-31 | EXAS | -0.89 | -4.15 | 2.76 |
| 2026-01-02 | EXAS | -0.89 | -4.15 | 2.76 |
| 2026-01-05 | EXAS | -0.89 | -4.16 | 2.77 |
| 2026-01-06 | EXAS | -0.73 | -4.16 | 2.77 |
| 2026-01-07 | EXAS | -0.73 | -4.16 | 2.77 |
| 2026-01-08 | EXAS | -0.73 | -4.16 | 2.77 |
| 2026-01-09 | EXAS | -0.73 | -4.16 | 2.77 |
| 2026-01-12 | EXAS | -0.73 | -4.15 | 2.77 |
| 2026-01-13 | EXAS | -0.73 | -4.15 | 4.59 |
| 2026-01-14 | EXAS | -0.72 | -4.15 | 4.56 |
| 2026-01-15 | EXAS | -0.73 | -4.15 | 4.56 |
| 2026-01-16 | EXAS | -0.73 | -4.15 | 4.56 |
| 2026-01-20 | EXAS | -0.73 | -3.64 | 4.56 |
| 2026-01-21 | EXAS | -0.73 | -3.64 | 4.56 |
| 2026-01-22 | EXAS | -0.73 | -3.64 | 4.56 |
| 2026-01-23 | EXAS | -0.73 | -3.64 | 4.56 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.24
Avg. EPS Est. Current Quarter
0.08
Avg. EPS Est. Next Quarter
0.1
Insider Transactions
-0.73
Institutional Transactions
-3.64
Beta
1.42
Average Sales Estimate Current Quarter
860
Average Sales Estimate Next Quarter
831
Fair Value
71.98
Quality Score
38
Growth Score
48
Sentiment Score
79
Actual DrawDown %
35.8
Max Drawdown 5-Year %
-80.4
Target Price
104
P/E
Forward P/E
272.18
PEG
P/S
6.33
P/B
7.74
P/Free Cash Flow
78.97
EPS
-5.32
Average EPS Est. Cur. Y
0.34
EPS Next Y. (Est.)
1.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-32.01
Relative Volume
0.34
Return on Equity vs Sector %
-66.7
Return on Equity vs Industry %
-50.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
1179.4
Exact Sciences CorporationSector: Healthcare
Industry: Diagnostics & Research
Employees: 6900
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
stock quote shares EXAS – Exact Sciences Corporation Stock Price stock today
news today EXAS – Exact Sciences Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch EXAS – Exact Sciences Corporation yahoo finance google finance
stock history EXAS – Exact Sciences Corporation invest stock market
stock prices EXAS premarket after hours
ticker EXAS fair value insiders trading